American Capital ACAS) Receives $182M from Sale of Axygen.

American Capital Ltd. (Nasdaq: ACAS) completed the sale of its portfolio company Axygen BioScience Inc., including its subsidiaries Axygen Inc. and Sorenson BioScience to Corning Incorporated for approximately $400M.

The total inception to date gain and income, including dividend and fee income, from the equity invested by American Capital's affiliated funds under management was $102M, representing a 25% compounded annual rate of return. American Capital (ACAS) received $182M in proceeds and realized a gain of $35M from the transaction, subject to post-closing adjustments